These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38007397)

  • 1. Patient Priorities Concerning Treatment Decisions for Advanced Neuroendocrine Tumors Identified by Discrete Choice Experiments.
    Anaka M; Chan D; Pattison S; Thawer A; Franco B; Moody L; Jackson C; Segelov E; Singh S
    Oncologist; 2024 Mar; 29(3):227-234. PubMed ID: 38007397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing Discrete Choice Experiment with Swing Weighting to Estimate Attribute Relative Importance: A Case Study in Lung Cancer Patient Preferences.
    Veldwijk J; Smith IP; Oliveri S; Petrocchi S; Smith MY; Lanzoni L; Janssens R; Huys I; de Wit GA; Groothuis-Oudshoorn CGM
    Med Decis Making; 2024 Feb; 44(2):203-216. PubMed ID: 38178591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
    Stueven AK; Kayser A; Wetz C; Amthauer H; Wree A; Tacke F; Wiedenmann B; Roderburg C; Jann H
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient Preferences Concerning Alternative Treatments for Neuroendocrine Tumors: Results of the "PIANO-Study".
    Mühlbacher AC; Juhnke C
    Int J Technol Assess Health Care; 2019 Jan; 35(3):243-251. PubMed ID: 31044688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
    Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M
    Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Patients' Priorities in the Treatment of Neuroendocrine Tumours: An Analytical Hierarchy Process].
    Mühlbacher AC; Juhnke C; Kaczynski A
    Gesundheitswesen; 2016 Oct; 78(10):651-657. PubMed ID: 26110243
    [No Abstract]   [Full Text] [Related]  

  • 7. Analysis of physicians' perspectives versus patients' preferences: direct assessment and discrete choice experiments in the therapy of multiple myeloma.
    Mühlbacher AC; Nübling M
    Eur J Health Econ; 2011 Jun; 12(3):193-203. PubMed ID: 20107856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
    Zhang J; Kulkarni HR; Singh A; Niepsch K; Müller D; Baum RP
    J Nucl Med; 2019 Mar; 60(3):377-385. PubMed ID: 30115686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laboratory, Clinical, and Survival Outcomes Associated With Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors.
    Kipnis ST; Hung M; Kumar S; Heckert JM; Lee H; Bennett B; Soulen MC; Pryma DA; Mankoff DA; Metz DC; Eads JR; Katona BW
    JAMA Netw Open; 2021 Mar; 4(3):e212274. PubMed ID: 33755166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does the inclusion of a cost attribute result in different preferences for the surgical treatment of primary basal cell carcinoma?: a comparison of two discrete-choice experiments.
    Essers BA; van Helvoort-Postulart D; Prins MH; Neumann M; Dirksen CD
    Pharmacoeconomics; 2010; 28(6):507-20. PubMed ID: 20387912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study.
    Kulke MH; Benson AB; Dasari A; Huynh L; Cai B; Totev T; Roesner N; Duh MS; Neary MP; Maurer VE; Shih BE; Dagohoy CG; Chan J; Bergsland EK
    Oncologist; 2019 Aug; 24(8):1056-1065. PubMed ID: 30606883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival or Mortality: Does Risk Attribute Framing Influence Decision-Making Behavior in a Discrete Choice Experiment?
    Veldwijk J; Essers BA; Lambooij MS; Dirksen CD; Smit HA; de Wit GA
    Value Health; 2016; 19(2):202-9. PubMed ID: 27021754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Systematic Review of Discrete Choice Experiments in Oncology Treatments.
    Collacott H; Soekhai V; Thomas C; Brooks A; Brookes E; Lo R; Mulnick S; Heidenreich S
    Patient; 2021 Nov; 14(6):775-790. PubMed ID: 33950476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unfavorable biological behavior and treatment response of neuroendocrine ovarian metastases of midgut neuroendocrine tumors.
    Mulders MCF; de Lussanet de la Sablonière QG; van Velthuysen MLF; Roes EM; Hofland J; de Herder WW
    Endocr Relat Cancer; 2023 Aug; 30(8):. PubMed ID: 37140986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Applying Reflective Multicriteria Decision Analysis (MCDA) to Patient-Clinician Shared Decision-Making on the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) in the Spanish Context.
    Wagner M; Samaha D; Cuervo J; Patel H; Martinez M; O'Neil WM; Jimenez-Fonseca P
    Adv Ther; 2018 Aug; 35(8):1215-1231. PubMed ID: 29987525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Impact of Radiological Response to Peptide Receptor Radionuclide Therapy on Overall Survival in Patients With Metastatic Midgut Neuroendocrine Tumors.
    Yalchin M; Oliveira A; Theocharidou E; Pencharz D; Navalkissoor S; Quigley AM; Walker M; Caplin M; Toumpanakis C
    Clin Nucl Med; 2017 Mar; 42(3):e135-e141. PubMed ID: 27922860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptide receptor radionuclide therapy for patients with advanced pancreatic neuroendocrine tumors.
    Ramage J; Naraev BG; Halfdanarson TR
    Semin Oncol; 2018 Aug; 45(4):236-248. PubMed ID: 30539715
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of survival with somatostatin analog and chemotherapy and prognostic factors for treatment in 165 advanced neuroendocrine tumor patients with Ki-67 20% or less.
    Özaslan E; Karaca H; Koca S; Sevinç A; Hacioğlu B; Özkan M; Özçelik M; Duran AO; Hacibekiroğlu İ; Yildiz Y; Tanriverdi Ö; Menekşe S; Aksoy A; Bozkurt O; Urvay S; Uysal M; Demir H; Çiltaş A; Dane F
    Anticancer Drugs; 2017 Feb; 28(2):222-229. PubMed ID: 27768606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Value of
    Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP
    J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptide receptor radionuclide therapy (PRRT) in metastatic neuroendocrine tumors of unknown primary (CUP-NETs).
    Baum RP; Wang P; Jakobsson V; Zhao T; Schuchardt C; Khong PL; Zhang J
    Theranostics; 2024; 14(1):133-142. PubMed ID: 38164147
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.